Erivedge and Neut
Determining the interaction of Erivedge and Neut and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:The solubility of vismodegib is known to be pH-dependent (0.1 mcg/mL at pH 7 and 0.99 mg/mL at pH 1) and drugs that alter the pH of the upper gastrointestinal tract may affects its solubility and reduce its bioavailability. However, a clinically significant pharmacokinetic effect has not been observed, with results from a clinical study showing a 33% reduction in the unbound drug concentrations of vismodegib after 7 days of concomitant therapy with the proton pump inhibitor rabeprazole (20 mg, given 2 hours before each vismodegib administration).
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Erivedge (vismodegib)." Genentech, South San Francisco, CA.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut 
Erivedge - Neut